No Data
Shenzhen Salubris Pharmaceuticals' Two Drugs Added to National Medical Insurance Catalog
Shenzhen Salubris Pharmaceuticals (002294.SZ): Alisartan, amlodipine besylate tablets and benzylidene-foglin tablets have been newly added to the national medical insurance catalog.
Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that according to the announcement released by the National Medical Insurance Administration and the Ministry of Human Resources and Social Security...
Shenzhen Salubris Pharmaceuticals (002294.SZ): Plans to increase capital by 30 million yuan to Pure Benchmark.
Gelonghui November 22nd | Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that, according to the company's global strategy development plan, Shenzhen Salubris Pharmaceuticals Co., Ltd. plans to increase its stake in the company Peking Symbol Technology (Beijing) Co., Ltd. referred to as 'Peking Symbol' or 'the target company') with self-raised funds of RMB 30 million, and obtain 3.2154% equity of Peking Symbol. After this capital increase is completed, the company will directly hold 8.5745% equity of Peking Symbol. Prior to the capital increase, the company and its subsidiary controlling enterprise Ningbo Meishan Bonded Port Zone Wo Sheng Jingjia Equity Investment Partnership Enterprise (Limited Partnership) (referred to as 'Wo Sheng Jingjia'),
The Five-year Decline in Earnings for Shenzhen Salubris Pharmaceuticals SZSE:002294) Isn't Encouraging, but Shareholders Are Still up 84% Over That Period
Does Shenzhen Salubris Pharmaceuticals (SZSE:002294) Have A Healthy Balance Sheet?
Shenzhen Salubris Pharmaceuticals to Increase Capital of US Subsidiary by About 350 Million Yuan
No Data
No Data